SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo says mipletamig combination enabled 21% of frontline AML patients to reach transplant

A filing reports that 21% of frontline AML patients advanced to stem cell transplant with the mipletamig combination.

APVO

Related stories